Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.59 -0.6%	$19.36	$10.21 ▼ $25.67	$4.20B	0.43	3.66 million shs	3.04 million shs
GPCR Structure Therapeutics	$19.53 -0.4%	$22.00	$13.22 ▼ $45.37	$1.12B	-1.87	829,844 shs	527,991 shs
KRYS Krystal Biotech	$150.15 +0.0%	$136.02	$122.80 ▼ $219.34	$4.34B	0.67	287,219 shs	266,341 shs
MTSR Metsera	$44.30 +1.3%	$29.73	$12.30 ▼ $46.43	$4.65B	N/A	904,555 shs	688,607 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-1.61%	-3.54%	-13.28%	-16.99%	+28.84%
GPCR Structure Therapeutics	+1.92%	+2.62%	-4.72%	-9.93%	-56.11%
KRYS Krystal Biotech	+1.59%	+0.79%	+12.81%	-10.97%	-28.04%
MTSR Metsera	+1.74%	+23.81%	+62.75%	+123.45%	+4,372,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8679 of 5 stars	3.7	1.0	0.0	0.0	2.8	2.5	3.1
GPCR Structure Therapeutics	2.927 of 5 stars	3.5	3.0	0.0	0.0	3.2	1.7	0.6
KRYS Krystal Biotech	4.5638 of 5 stars	3.5	1.0	0.0	4.7	2.2	3.3	1.9
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	57.29% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	290.00% Upside
KRYS Krystal Biotech	3.00	Buy	$213.75	42.36% Upside
MTSR Metsera	3.00	Buy	$55.00	24.15% Upside

Current Analyst Ratings Breakdown

Latest GPCR, MTSR, ADMA, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.85	$0.53 per share	33.22	$1.48 per share	11.89
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
KRYS Krystal Biotech	$290.52M	14.94	$4.71 per share	31.86	$32.90 per share	4.56
MTSR Metsera	N/A	N/A	N/A	N/A	($2.46) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	20.69	25.49	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	36.09	14.90	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest GPCR, MTSR, ADMA, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
GPCR Structure Therapeutics	N/A	23.29	23.29
KRYS Krystal Biotech	N/A	9.65	9.27
MTSR Metsera	N/A	6.55	6.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
GPCR Structure Therapeutics	91.78%
KRYS Krystal Biotech	86.29%
MTSR Metsera	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
GPCR Structure Therapeutics	9.43%
KRYS Krystal Biotech	13.70%
MTSR Metsera	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A

GPCR, MTSR, ADMA, and KRYS Headlines

Recent News About These Companies

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

July 14 at 11:20 AM | finance.yahoo.com

Alphabet Inc. Takes $135.06 Million Position in Metsera Inc. (NASDAQ:MTSR)

July 14 at 6:56 AM | marketbeat.com

Metsera (NASDAQ:MTSR) Sets New 52-Week High - What's Next?

July 11, 2025 | marketbeat.com

Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

July 10, 2025 | zacks.com

Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why

July 10, 2025 | zacks.com

Metsera Clears Key Benchmark, Hitting 90-Plus RS Rating

July 9, 2025 | msn.com

Metsera (NASDAQ:MTSR) Trading Up 6.3% - What's Next?

July 9, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Stock Price Up 10.3% - Here's Why

July 2, 2025 | marketbeat.com

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Nasdaq

June 26, 2025 | nasdaq.com

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

June 24, 2025 | zacks.com

Metsera (NASDAQ:MTSR) Trading Down 6.3% - What's Next?

June 23, 2025 | marketbeat.com

Wells Fargo Initiates Coverage of Metsera (MTSR) with Overweight Recommendation

June 20, 2025 | msn.com

Metsera (NASDAQ:MTSR) Coverage Initiated by Analysts at Wells Fargo & Company

June 20, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Trading 6.4% Higher - Still a Buy?

June 18, 2025 | marketbeat.com

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review

June 12, 2025 | seekingalpha.com

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results

June 11, 2025 | msn.com

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med

June 11, 2025 | medcitynews.comM

Metsera extends gains after early-stage trial data for obesity therapy

June 10, 2025 | msn.com

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating

June 10, 2025 | msn.com

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 10, 2025 | globenewswire.com

Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

June 9, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, MTSR, ADMA, and KRYS Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.59 -0.10 (-0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$17.52 -0.07 (-0.40%)

As of 06:48 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Structure Therapeutics NASDAQ:GPCR

$19.53 -0.07 (-0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$19.90 +0.37 (+1.89%)

As of 06:35 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$150.15 +0.07 (+0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$150.12 -0.03 (-0.02%)

As of 05:43 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Metsera NASDAQ:MTSR

$44.30 +0.57 (+1.30%)

As of 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time